GRASPA Treatment for Patients With Acute Myeloblastic Leukemia
Status:
Completed
Trial end date:
2017-11-10
Target enrollment:
Participant gender:
Summary
The protocol aims at adding GRASPA (L-asparaginase encapsulated in red blood cells,
eryaspase) to standard chemotherapy (low-dose cytarabine) to treat patients older than 65
years diagnosed with AML and unfit for intensive chemotherapy.